Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors

Pituitary Tumors Clinical Trial

Official title:
A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors

Status Completed

Clinical Trial Summary

Many types of cancers overexpress a receptor for the vitamin folate (Folate Receptor). This Phase 2 study will utilize a standard imaging radionuclide, technetium-99m, conjugated to a ligand (EC20) designed to bind to the folate receptor. The study is designed as an open-label, baseline-controlled study.

Clinical Trial Description

This is a Phase 2 open-label, single-treatment group, baseline-controlled study designed to verify product safety, gather data on the percentage of subjects with pituitary tumors with increased uptake of FolateScan in tumors and correlate the immunohistochemical staining findings with the FolateScan images, in subjects with pituitary tumors. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01689727
Study type	Interventional
Source	Endocyte
Contact
Status	Completed
Phase	Phase 2
Start date	September 2002

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01903967` - Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH)	N/A
Completed	`NCT01322945` - Barrow Nasal Inventory Survey	N/A
Completed	`NCT00565903` - Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
Completed	`NCT01794793` - Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies	Phase 4
Completed	`NCT00462475` - Effect of 5 Years of GH Replacement on Atherosclerosis	Phase 4
Recruiting	`NCT05634655` - Dissecting the Mechanism of DNA Methylation on the Invasiveness of Pituitary Tumors.